Oncotelic Therapeutics, Inc. — Income Charts
48 quarters of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
Cost of Revenue
$0
R&D↓-83.4% -$55K
$11K
D&A↓-100.0% -$3K
$0
Operating Income↑+102.4% +$610K
$14K
EBITDA↑+102.4% +$610K
$14K
Interest Expense↓-78.6% -$764K
$208K
Interest Income↓-99.0% -$990
$10
Net Income↑+114.8% +$893K
$115K
Operating Margin
20.7%
Net Margin
164.7%
Deferred Tax Assets
$500K
DTA Valuation Allowance↓-99.9% -$67M
$45K
NOL Carryforwards↓-99.7% -$56M
$189K
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↓-13.0pts
21.0%
ETR State + Local (pp)↓-0.9pts
-0.7%
Operating Lease Cost
$0
Revenue YoY Variation
-100.0%
Income YoY Variation↑+35.3pts
102.4%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↑+232.5pts
100.2%